/
HTGC
$15.83+$0.24 (+1.57%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.9B
187M shares
52-week range
$13.70 – $19.67
36% from low
Exchange
NYSE
CS
Borrow rate
1.20%
Moderate
Price (6 mo)
Loading chart…
Change$-1.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $175.5M | $298.2M | $357.4M | $309.6M | $239.4M | $494.1M | $430.9M | $547.1M |
| Cost of revenue | $39.4M | $54.6M | $59.6M | $54.4M | $54.7M | $67.6M | $77.2M | $69.8M |
| Gross profit | $136.1M | $243.6M | $297.8M | $255.1M | $184.6M | $426.5M | $353.7M | $477.3M |
| Gross margin | 77.5% | 81.7% | 83.3% | 82.4% | 77.1% | 86.3% | 82.1% | 87.2% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $76.5M | $173.6M | $227.3M | $174.2M | $102.1M | $337.5M | $263.0M | $365.2M |
| EBITDA | $76.7M | $173.9M | $227.7M | $174.5M | $102.3M | $337.7M | $263.4M | $365.4M |
| Net income | $76.5M | $173.6M | $227.3M | $174.2M | $102.1M | $337.5M | $263.0M | $339.7M |
| Net margin | 43.6% | 58.2% | 63.6% | 56.3% | 42.6% | 68.3% | 61.0% | 62.1% |
| EPS (diluted) | 0.83 | 1.71 | 2.01 | 1.49 | 0.79 | 2.31 | 1.61 | 1.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $586M | $1.93 | $1.89–$1.97 | 6 |
| 2027 | $633M | $1.97 | $1.94–$2.00 | 6 |
| 2028 | $685M | $1.91 | $1.83–$2.00 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$88.81
Price
$15.82
Implied upside
+461%
Peer comparison
Hercules Capital, Inc.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
www.htgc.com- Employees
- 50
- IPO / List date
- Jun 9, 2005
- HQ
- SAN MATEO, CA
Held by traders on TradeandTell
No one on the platform currently holds HTGC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HTGC as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 5.94% ($0.94/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-14 | $0.4000 | 2026-05-21 |
| 2026-05-14 | $0.0700 | 2026-05-21 |
| 2026-02-25 | $0.0700 | 2026-03-04 |
| 2026-02-25 | $0.4000 | 2026-03-04 |
| 2025-11-12 | $0.4000 | 2025-11-19 |
| 2025-11-12 | $0.0700 | 2025-11-19 |
| 2025-08-12 | $0.0700 | 2025-08-19 |
| 2025-08-12 | $0.4000 | 2025-08-19 |
| 2025-05-13 | $0.0700 | 2025-05-20 |
| 2025-05-13 | $0.4000 | 2025-05-20 |
Recent trades on TradeandTell
No one on the platform has traded HTGC yet.
